|
|
|
Start with Aricept. Stay with Aricept
|
Start with Aricept.
for efficacy in mild, moderate and severe Alzheimer's disease.
Stay with Aricept.
for patients who benefit from treatment.
Donepezil, marketed under the trade name Aricept (Eisai), is a centrally acting reversible acetylcholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. It has an oral bioavailability of 100% and easily crosses the blood-brain barrier. Because it has a half life of about 70 hours, it can be taken once a day. Initial dose is 5 mg per day, which can be increased to 10 mg per day after an adjustment period of at least 4 weeks.
|
|
| Rate this file (No vote yet) |
|
|
|
|
|
|
